10-K: Therapeutic Solutions International Reports Full Year 2023 Results, Cites Ongoing Losses and Need for Capital

Therapeutic Solutions International reports a net loss of $2.2 million for 2023, highlighting ongoing financial challenges and the need for additional capital.

Summary

• Therapeutic Solutions International (TSOI) reported a net loss of approximately $2.2 million for the year ended December 31, 2023, compared to a net loss of $3.8 million in 2022.
• Net sales decreased to $98,994 in 2023 from $206,767 in 2022, primarily due to a decline in nutraceutical product sales.
• Operating expenses decreased by $1.4 million, from $3.4 million in 2022 to $2 million in 2023, due to reduced selling expenses and research and development costs.
• The company's accumulated deficit reached $20.1 million as of December 31, 2023.
• TSOI's management has expressed substantial doubt about the company's ability to continue as a going concern, citing recurring losses and the need for additional financing.
• The company is focused on immune modulation for the treatment of various diseases, including cancer, schizophrenia, and traumatic brain injury.
• TSOI is developing a range of immune-modulatory agents and has a nutraceutical division producing products like QuadraMune.
• The company has also obtained rights to a patented adult stem cell, JadiCell, for regenerative medicine applications.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including substantial losses, declining revenue, and a going concern warning. While there are some positive aspects, such as patent filings and subsidiary formations, the overall sentiment is negative due to the company's financial instability and operational risks.

Positives

• Operating expenses decreased by $1.4 million year-over-year, indicating cost-cutting measures.
• Research and development costs decreased by approximately $891,000, which may reflect a more focused approach.
• The company has a diverse portfolio of patents and patent applications related to its technologies.
• TSOI has established several subsidiary companies to focus on specific therapeutic areas, such as CTE, COPD, and breast cancer.

Negatives

• The company experienced a significant decrease in net sales, from $206,767 in 2022 to $98,994 in 2023.
• The company's net loss remains substantial at $2.2 million for 2023.
• TSOI has an accumulated deficit of $20.1 million, indicating a history of losses.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company has material weaknesses in its internal control over financial reporting.

Risks

• The company's internal control over financial reporting is not effective, which could lead to unreliable financial reporting.
• TSOI needs to raise additional capital to fund its operations, and there is no guarantee that such capital will be available.
• The company has a limited operating history in its new business model and limited experience introducing new products.
• The company faces significant competition in the biotechnology, biopharma, and nutraceutical industries.
• The company's common stock is currently classified as a penny stock, which may make it difficult for investors to sell their shares.
• The company's stock price may experience future volatility and is considered illiquid.

Future Outlook

The company's management believes that its current cash and cash equivalents will not be sufficient to meet its anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements. The company intends to raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements.

Management Comments

• Management has concluded that the company's internal control over financial reporting is not effective.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• Management is committed to meeting or exceeding the standards set by the FDA.

Industry Context

The biotechnology, biopharma, and nutraceutical industries are subject to rapid technological change and intense competition. TSOI faces competition from both domestic and foreign companies, including large pharmaceutical companies with greater resources.

Comparison to Industry Standards

• The company's financial performance, particularly the significant net losses and declining revenue, is concerning when compared to industry benchmarks.
• Many established companies in the nutraceutical and biopharma sectors have significantly higher revenue and profitability.
• The company's reliance on external funding and the going concern warning are not typical for mature companies in these industries.
• The company's research and development spending, while decreased, is still a significant portion of its expenses, which is common in the biotech industry but needs to be balanced with revenue generation.

Legal Proceedings

• TSOI has filed suit against anonymous online posters for defamation.
• The company is involved in a lawsuit with Kyle Shepard, Dr. James Veltmeyer, and Dr. Thomas Ichim for fraud, breach of fiduciary duty, conversion, accounting action, and intentional interference with contracts.

Related Party Transactions

• The company has unsecured interest-bearing demand notes outstanding to certain officers and directors.
• The company has issued shares of common stock to officers and directors as compensation.

Stakeholder Impact

• Shareholders face the risk of further dilution due to potential equity offerings.
• Employees may be affected by potential cost-cutting measures or operational changes.
• Customers may be impacted by changes in product availability or pricing.
• Creditors face the risk of non-payment due to the company's financial instability.

Next Steps

• The company plans to continue to raise additional capital to fund its operations.
• The company will continue to prioritize its commercialization of products and clinical trial strategy.
• The company will continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of complex transactions.
• The company will continue to enhance information security measures to investigate and remediate any information security vulnerabilities.

Key Dates

Keywords

immune modulation, stem cell therapy, nutraceuticals, JadiCell, QuadraMune, regenerative medicine, immunotherapy, chronic traumatic encephalopathy, COPD, breast cancer, financial results, patent, biotechnology